About Imbed Biosciences
Imbed Biosciences is a Technology company based in Madison (United States) founded in 2010. Nanotech-based wound care products are developed and provided. It operates in the Technology, Healthcare, and Aerospace, Defense & Maritime sectors. Imbed Biosciences has raised $22.7 million across 19 funding rounds from investors including NIH, HHS and Niterra Ventures. The company has 35 employees. Imbed Biosciences offers products and services including Surgaflex, PelashieldAM, and Microlyte Matrix. Its focus areas include Aerospace, Maritime and Defense Tech, Military Tech, Healthcare Solutions and Therapeutic Devices. Its legal entity is IMBED BIOSCIENCES, INC. Its competitors include Cresilon, Cour Pharma and Alafair Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Imbed Biosciences was founded in 2010 and is based in Madison, United States. Focus is placed on the biotechnology sector, where nanotechnology is applied to wound care. Bioactive molecules are embedded into dressings and surgical implants via the Microlyte Matrix platform. Antibacterial, anti-biofilm, and analgesic wound dressings are produced for medical use. Operations center on advancing these technologies for clinical applications.
- Total Equity Funding$22.7M (USD)
in 19 rounds
- InvestorsNIH
& 7 more
- Employee Count35
Products & Services of Imbed Biosciences
Imbed Biosciences offers a comprehensive portfolio of products and services, including Surgaflex, PelashieldAM, and Microlyte Matrix.
Antimicrobial matrix for surgical wounds management.
Hydrophilic matrix for complex burn wound challenges.
Synthetic skin substitute for chronic wound healing.
Funding Insights of Imbed Biosciences
Imbed Biosciences has successfully raised a total of $22.7M across 19 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22.7M
- Total Rounds 19
- Investors Count 8
Latest 10 of 19 funding rounds of Imbed Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | Series C | – | – | ||
| Jan 2024 | $10M | Debt – Convertible | – | Niterra | – |
| Dec 2023 | $3.5M | Series B | – | – | – |
| May 2023 | $2.5M | Series B | – | – | – |
| Nov 2021 | $7.89M | Series B | – | – | – |
| Oct 2021 | $800,000 | Grant | – | – | |
| Sep 2021 | $806,430 | Grant | – | – | |
| Jun 2020 | $1.49M | Series A | – | – | – |
| Oct 2019 | $4.03M | Series A | – | Formidable Asset Management | |
| Sep 2019 | $1.5M | Grant | – | – |
8 investors in total: 8 institutional.
Investors in Imbed Biosciences
Imbed Biosciences has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Niterra Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Innovative ideas are transformed into reality by Niterra Ventures. | niterraventures.com | Tokyo, Japan | ||
WISC Partners is engaged in providing expansion and acceleration capital. | wiscpartners.com | Madison, United States | ||
Early-stage entrepreneurs are accelerated through MassChallenge's program. | masschallenge.org | Boston, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Offers active asset management, financial planning, and insurance services to individuals. | 2013 | formidableam.com | Cincinnati, United States | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
| biolabholdings.com |
Investor details for Imbed Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Imbed Biosciences
5 people are tracked at Imbed Biosciences (4 in leadership, 1 in board & advisors); the tracked headcount is 35.
| Name | Role | Group |
|---|---|---|
Gaurav Pranami | VP Of R&d | Leadership |
Ankit Agarwal | Founder, CSO | Leadership |
Dave Posten | Vice President Of Sales | Leadership |
Brad Wiggins | Vice President Clinical Affairs | Leadership |
Michael J. Schurr | Director & Co-Founder | Board & advisors |
Complete people profiles for Imbed Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Imbed Biosciences
3 dated milestones of Imbed Biosciences across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Imbed Biosciences is founded.
- Funding First funding round.
- Funding Latest funding round, Series C,.
Competitors of Imbed Biosciences
Imbed Biosciences has 3 listed competitors in our database, 3 of them funded. They include Cresilon, Cour Pharma and Alafair Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cresilon.com | 2010 | New York, United States | $106.67M | 73 | Developer of hemostatic products for wound care | |
| courpharma.com | 2013 | Chicago, United States | $135.2M | 31 | Biotech nanoparticles are developed for immune disease treatments. | |
| alafairbiosciences.com | 2011 | Austin, United States | $13.74M | Biomaterials and devices for internal wound healing are developed. |
Detailed competitors of Imbed Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Imbed Biosciences
The website of Imbed Biosciences (imbedbio.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▼ 24.6% vs previous month
Websites whose visitors overlap most with Imbed Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Nanotechnology
3 companies that operate in the same segment as Imbed Biosciences (Nanotechnology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of technologies for analysis of genetic variation and function | 1993 | San Diego, California, United States | USD 28 M | USD 1.44 M | 29 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Imbed Biosciences
Complete news archive for Imbed Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Imbed Biosciences
Imbed Biosciences was founded in 2010.
Imbed Biosciences is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.
Imbed Biosciences is a funded company, having raised a total of $22.7M across 19 funding rounds to date. The company's 1st funding round was a Grant of $1.5M, raised on Jun 2010.
Imbed Biosciences has 35 employees.
Imbed Biosciences was founded in 2010 and is based in Madison, United States. Focus is placed on the biotechnology sector, where nanotechnology is applied to wound care. Bioactive molecules are embedded into dressings and surgical implants via the Microlyte Matrix platform. Antibacterial, anti-biofilm, and analgesic wound dressings are produced for medical use. Operations center on advancing these technologies for clinical applications.
Imbed Biosciences's top competitors include Cresilon, Cour Pharma and Alafair Biosciences.
Imbed Biosciences offers Surgaflex, PelashieldAM, and Microlyte Matrix.
Imbed Biosciences has 8 investors. Key investors include NIH, HHS, Niterra Ventures, Formidable Asset Management, and WISC Partners.
Imbed Biosciences operates through Imbed Biosciences, Inc..